Every drug actually has three distinct names: a chemical name describing its molecular structure, a generic name assigned by an official naming body, and a brand name created by the company that sells it. These names are assigned at different stages of development, each serving a different purpose, and the process involves scientists, regulatory agencies, and international committees working to keep things consistent and safe.
The Three Names Every Drug Gets
A drug’s chemical name comes first, assigned when the compound is initially discovered. It describes the exact atomic and molecular structure of the substance using standardized chemistry rules set by the International Union of Pure and Applied Chemistry (IUPAC). These names are precise but practically unusable in everyday settings. Ibuprofen’s chemical name, for example, is (RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid. Chemical names include details like which atoms are bonded where, the three-dimensional arrangement of the molecule, and whether the compound is a salt or has other chemical forms.
The generic name is the one doctors, researchers, and pharmacists use. It’s a simplified, nonproprietary name that refers to the drug itself rather than any specific company’s version of it. In the United States, the generic name is assigned by the United States Adopted Names (USAN) Council, a body run through the American Medical Association. Many generic names are essentially shorthand versions of the chemical name or formula.
The brand name is the marketing name, developed by the pharmaceutical company seeking approval to sell the drug. Brand names are designed to be catchy and easy to remember, often hinting at what the drug treats. Sometimes the brand name is just a trimmed-down version of the generic name, like Minocin for minocycline. The FDA must approve every proposed brand name before a company can use it.
How Generic Names Are Chosen
The process starts when a pharmaceutical company files an application with the USAN Council, which includes documentation proving the proposed names don’t conflict with existing trademarks or generic names. Program staff then verify the drug’s chemistry, search databases for related compounds, and figure out how the drug fits into the broader naming system.
Council members evaluate proposed names against several criteria. The name should reflect the drug’s action or class, fit into the existing naming scheme, translate well into other languages, and be easy to pronounce and remember. It also needs to be useful to healthcare providers in practice. The FDA weighs in through a representative on the Council. Before a name is finalized, three parties must agree: the sponsoring company, the USAN Council, and the World Health Organization’s International Nonproprietary Names (INN) Expert Group. This consensus requirement is what keeps drug names consistent around the world.
The Hidden Code in Drug Name Endings
If you’ve ever noticed that certain drugs have similar-sounding endings, that’s by design. Generic drug names contain standardized stems, usually suffixes, that tell pharmacists and doctors exactly what class of drug they’re looking at. Once you know the system, a drug’s name reveals what it does.
- -olol (like metoprolol, atenolol): beta blockers used for high blood pressure
- -pril (like lisinopril, enalapril): ACE inhibitors, also for blood pressure
- -statin (like atorvastatin, rosuvastatin): cholesterol-lowering drugs
- -cillin (like amoxicillin, ampicillin): penicillin-type antibiotics
- -cycline (like doxycycline, tetracycline): a different class of antibiotics
- -triptan (like sumatriptan, rizatriptan): migraine medications
- -afil (like sildenafil, tadalafil): drugs that relax blood vessels, used for erectile dysfunction and pulmonary hypertension
- -caine (like lidocaine, procaine): local anesthetics
- -artan (like losartan, valsartan): another class of blood pressure drugs
- -navir (like ritonavir, lopinavir): antiviral drugs that block a key enzyme viruses need to replicate
- -azole (like fluconazole, ketoconazole): antifungal medications
- -etine (like fluoxetine, paroxetine): SSRIs used for depression
These stems are part of the naming scheme that the USAN Council and WHO maintain together. When a new drug is developed, it gets slotted into the appropriate stem category based on how it works, which is why drugs in the same class always sound like relatives.
When Each Name Gets Assigned
Drug naming doesn’t happen all at once. It follows the stages of clinical development. Companies can first request a generic name from the USAN Council during Phase 1 trials, the earliest human safety studies. Most U.S. companies apply during Phase 2, when the drug is being tested for effectiveness. The generic name is typically finalized and published during Phase 3, the large-scale trials that happen before the drug goes to regulators for approval.
Brand names follow a parallel but slightly different track. Companies may file planned trade names with the U.S. Patent and Trademark Office as early as the preclinical stage, before any human testing begins. During Phase 2, they can submit the brand name to the FDA for review with supporting documentation. But the brand name doesn’t receive final FDA approval until the company submits its full application for the drug to go to market. That means a drug can go through years of clinical trials under its generic name before anyone outside the company ever hears the brand name.
Global Coordination Through the WHO
The World Health Organization runs the International Nonproprietary Names (INN) program, which works to ensure that every active pharmaceutical ingredient has a single globally accepted name. The WHO collaborates with national naming committees around the world, and the result is that names assigned in different countries are now, with rare exceptions, identical. The U.S. Adopted Name, the British Approved Name, the French common name, and the Japanese Adopted Name for a given drug are almost always the same as the INN.
This matters because it prevents confusion when drugs cross borders. A doctor reading a study published in Japan, a pharmacist filling a prescription in Brazil, and a regulator reviewing safety data in Germany are all referring to the same compound by the same name. To protect this system, the WHO discourages companies from deriving trademarks from INNs or using the standardized stems in their brand names, since that could blur the line between the generic identity and a specific company’s product.
Biologic Drugs Have an Extra Layer
Biologic drugs, which are made from living cells rather than chemical synthesis, follow a newer naming convention. Each biologic gets a core name plus a four-letter suffix attached with a hyphen. The suffix is deliberately meaningless: it must be four lowercase letters, at least three of which are distinct, and it can’t suggest any drug name, company name, or abbreviation used in clinical practice.
This system exists because biologics made by different manufacturers aren’t identical the way generic pills are. The suffix lets pharmacists and doctors distinguish between different versions of the same biologic. When a company applies for approval, it submits up to 10 proposed suffixes in order of preference. If none pass FDA review, the agency assigns one itself. The suffix can’t look similar to any existing product name or be capable of causing confusion in a clinical setting.
Preventing Mix-Ups Between Similar Names
One of the biggest safety concerns in drug naming is that two drugs can end up with names that look or sound dangerously alike. The Institute for Safe Medication Practices (ISMP) maintains a list of commonly confused drug name pairs, and the solution used in hospitals and pharmacies is called Tall Man lettering. Specific letters within a drug’s name are capitalized to highlight the differences between lookalike pairs.
Some examples show how subtle the similarities can be: hydrALAZINE (a blood pressure drug) versus hydroCHLOROthiazide (a diuretic), prednisoLONE versus predniSONE (two different steroids), vinBLAStine versus vinCRIStine (two chemotherapy drugs with very different uses), and HYDROmorphone versus oxyMORphone (two opioids with different potencies). In the case of ePHEDrine versus EPINEPHrine, a mix-up could be life-threatening. The capitalized letters act as a visual speed bump, forcing the reader to slow down and confirm they have the right drug.
This is also why the FDA reviews proposed brand names before they can be used. A name that looks too similar to an existing product on a handwritten prescription, or sounds too close when spoken aloud in a busy pharmacy, can be rejected before it ever reaches the market.